To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed
Dopamine decarboxylase inhibitors prevent the conversion of levodopa to dopamine in the periphery, allowing for more levodopa to cross the BBB
Conversion of levodopa to 3-O-methyldopa and dopamine to 3-O-methyldopamine by catechol-O-methyltransferase (COMT) is an important metabolic pathway, especially
It calculates the contribution made by each of your Parkinson's drugs
DDC acting as decarboxylase inhibitor makes COMT main metabolic pathway catalyzing this conversion of Levodopa
© 2023 The Authors
Oral challenges with 3OMD reduce the clinical response to levodopa infusions, but 3OMD is no more potent than phenylalanine in this regard
Literature published up to September 2021 was collected in the PubMed, Web of Science, and Embase by using search strategy (“levodopa” OR “l-DOPA”) AND (“chromatography”)
l -DOPA is an amino acid, so protein competitively inhibits l -DOPA absorption
Since COMT requires Mg2+ and S-adenosylmethionine as methyl donor for this transmethylating process, COMT converts S-adenosylmethionine to S-adenosylhomocysteine and subsequent homocysteine
In addition, 3-OMD contributes to the total amount of LNAA, and competes with levodopa for absorption and transportation by the LAAT in the blood–brain barrier [24, 25]
安全性
tolcapone (本邦未承認)で After oral levodopa administration, COMT activity in the GI tract converts a significant fraction of levodopa to 3-OMD, reducing the amount of levodopa available to the CNS
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed
The catabolism of L-DOPA to synthesize 3-OMD
Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al
We have 3 created an easy-to-use application that allows for the calculation
We studied 19 patients (14 men, 5 women, Hoehn and Yahr (H&Y)> or =3) with advanced Parkinson's disease (PD) attending the Parkinson Institute, Milan
Tomlinson et al